Skip to main content

The independent source for health policy research, polling, and news.

Subscribe Follow Us Donate
  • Trump 2.0

    Trump 2.0

    • Agency Watch
    • State Watch
    • Rural Health Payout
  • Public Health

    Public Health

    • Vaccines
    • CDC & Disease
    • Environmental Health
  • Audio Reports

    Audio Reports

    • What the Health?
    • Health Care Helpline
    • KFF Health News Minute
    • An Arm and a Leg
    • Health Hub
    • HealthQ
    • Silence in Sikeston
    • Epidemic
    • See All Audio
  • Special Reports

    Special Reports

    • Bill Of The Month
    • The Body Shops
    • Broken Rehab
    • Deadly Denials
    • Priced Out
    • Dead Zone
    • Diagnosis: Debt
    • Overpayment Outrage
    • Opioid Settlement Tracking
    • See All Special Reports
  • More Topics

    More Topics

    • Elections
    • Health Care Costs
    • Insurance
    • Prescription Drugs
    • Health Industry
    • Immigration
    • Reproductive Health
    • Technology
    • Rural Health
    • Race and Health
    • Aging
    • Mental Health
    • Affordable Care Act
    • Medicare
    • Medicaid
    • Children’s Health

  • Surgeon General
  • Cigna’s ACA Exit
  • Visa Program
  • Medicaid Work Requirements
  • Gavin Newsom

TRENDING TOPICS:

  • Surgeon General
  • Cigna's ACA Exit
  • Visa Program
  • Medicaid Work Requirements
  • Gavin Newsom

Morning Briefing

Summaries of health policy coverage from major news organizations

  • Email

Wednesday, Feb 2 2022

Full Issue

More Good News About Remdesivir

Read about the biggest pharmaceutical developments and pricing stories from the past week in KHN's Prescription Drug Watch roundup.

New England Journal of Medicine: Early Remdesivir To Prevent Progression To Severe Covid-19 In Outpatients 

Remdesivir improves clinical outcomes in patients hospitalized with moderate-to-severe coronavirus disease 2019 (Covid-19). Whether the use of remdesivir in symptomatic, nonhospitalized patients with Covid-19 who are at high risk for disease progression prevents hospitalization is uncertain. (Gottlieb, M.D., Ph.D., et al, 1/27)

ScienceDaily: Making RNA Vaccines Easier To Swallow 

Researchers developed a way to deliver RNA in a capsule that can be swallowed, which could make RNA vaccines easier to tolerate. It could also make it easier to deliver other kinds of therapeutic RNA or DNA directly to the digestive tract, to help treat gastrointestinal disorders. (Massachusetts Institute of Technology, 1/31)

In other pharmaceutical news —

CBS Miami: Florida Senate Signs Off On Telehealth Prescription Proposal 

The Florida Senate has unanimously passed a measure that would expand doctors’ ability to prescribe certain controlled substances when treating patients through telehealth. Doctors are currently prohibited from prescribing controlled substances when using telehealth, except in the treatment of patients with psychiatric disorders, inpatients at hospitals and patients in hospice care or nursing home facilities. (1/28)

Miami Herald: Make Sure Prescription Drug Is Right Before Leaving Pharmacy 

The increased demand for COVID tests and vaccinations has left many pharmacies understaffed. Because of this, your pharmacist may be working very quickly, and mistakes can happen. In our Miami dermatology practice, we are seeing an increase in the number of prescriptions that have been filled with the wrong medication. (Baumann, M.D., 1/28)

CIDRAP: New Coalition To Focus On Antibiotic Overuse In Agriculture

US PIRG (Public Interest Research Group) Education Fund today announced the launch of a new coalition dedicated to reducing antibiotic use in agriculture. The Coalition to Preserve Antibiotics includes physicians, farmers, and animal and public health professionals. The group says in it mission statement that while overuse of antibiotics in any setting can promote the development of antibiotic-resistant bacteria, its focus is on reducing antibiotic use in agriculture because roughly two thirds of the medically important antibiotics sold in the United States are for use in food-producing animals. (1/27)

CIDRAP: AMR Action Fund Head Aims To Boost Innovation, Funds For New Antibiotics 

The news about the antibiotic development in recent years has been, for lack of a better word, rather bleak. Many large pharmaceutical companies have abandoned antibiotic research and development (R&D) because of the poor return on investment. Smaller companies have gone bankrupt after getting a new antibiotic approved, for the very same reason. Multiple analyses have found that the pipeline to replace some of the antibiotics we've relied on for decades has some very good candidates for deadly, multidrug-resistant pathogens, but not enough. And too few of them are truly innovative. (Dall, 1/27)

Nature Medicine: Polypills For The Prevention Of Cardiovascular Disease: A Framework For Wider Use 

Combinations of cardiovascular medications taken in a single pill — known as polypills — are effective but not widely used, requiring a global shift from physicians, regulators and drug developers. Cardiovascular diseases (CVDs) are the leading cause of premature death and disability globally, with disease burden continuing to rise in low- and middle-income countries (LMICs)1. Safe and effective preventive treatments for CVDs, such as blood-pressure-lowering drugs, statins and aspirin, have been available for decades. However, most people in LMICs that are at sufficiently increased CVD risk to warrant use of these medications do not receive them2,3. (Patel, et al, 1/31)

This is part of the Morning Briefing, a summary of health policy coverage from major news organizations. Sign up for an email subscription.
Newsletter icon

Sign Up For Our Newsletter

Stay informed by signing up for the Morning Briefing and other emails:

Recent Morning Briefings

  • Friday, May 1
  • Thursday, April 30
  • Wednesday, April 29
  • Tuesday, April 28
  • Monday, April 27
  • Friday, April 24
More Morning Briefings
RSS Feeds
  • Podcasts
  • Special Reports
  • Morning Briefing
  • About Us
  • Donate
  • Staff
  • Republish Our Content
  • Contact Us

Follow Us

  • Instagram
  • YouTube
  • LinkedIn
  • Facebook
  • X
  • Bluesky
  • TikTok
  • RSS

Sign up for emails

Join our email list for regular updates based on your personal preferences.

Sign up
  • Editorial Policy
  • Privacy Policy

© 2026 KFF